心脑舒通胶囊治疗脑梗死临床疗效及对血清高敏C反应蛋白的影响

摘要

Objective To assess the curative effect of Xinnaoshutong capsule in cerebral infarction and its effect on serum high-sensitivity C-reactive protein(hs-CRP). Methods One hundred and twenty patients with cerebral infarction were randomly divided into Xinnaoshutong group treated by Xinnaoshutong capsule and conventional treatment group. National institute of Health Stroke Scale (NIHSS) score and activities of daily living(ADL) scale bathel index and serumhs CRP were assessed 30 days after treatment. Results NIHSS score in Xinnaoshutong capsule group was significantly different from that in control group 30 days after treatment ( P ＜ 0.05 ). Bathel index score in Xinnaoshutong group was significantly different from that in control group at 30 days ( P ＜ 0.05 ). Serum concentration of hs-CRP in Xinnaoshutong capsule group was significantly different from that in the control group ( P ＜ 0.05 ). Conclusion Xinnaoshutong capsule is effective of reducing serum concentration of hs-CRP in cerebral infarction.%目的 评价心脑舒通胶囊对脑梗死临床疗效及对患者血清高敏C-反应蛋白(hs-CRP)的影响.方法 选择2006年9月至2009年8月漳州市中医院神经内科收治的脑梗死患者120例,完全随机分为治疗组和对照组.治疗组应用心脑舒通胶囊,3粒/次,3次/d,口服.对照组应用吡拉西坦片,2粒/次,3次/d,口服.30 d后评定2组总疗效,采用美国国立卫生院神经功能缺损评分(NIHSS)评分和日常生活活动能力Bathel指数评分(ADL评分)评价神经功能恢复情况;并测定治疗前后血清hs-CRP.结果 治疗组62例,痊愈17例(27.4%),显效35例(56.4%),有效6例(9.7%),无效4例(6.5%),总有效率93.5%.对照组58例,痊愈11例(19.0%),显效13例(22.4%),有效18例(31.0%),无效16例(27.6%),总有效率72.4%.治疗组30 d的NIHSS评分与对照组比较有统计学意义(P＜0.05),2组NIHSS评分治疗后较治疗前均有统计学意义(P＜0.05),治疗组治疗后30 d ADL评分与对照组比较有统计学意义(P＜0.05),2组ADL评分治疗后较治疗前差异均有统计学意义(P＜0.05).治疗组与对照组血清hs-CRP下降浓度比较差异有统计学意义(P＜0.05).结论 心脑舒通胶囊可降低脑梗死患者血清hs-CRP浓度,对脑梗死有较好的疗效.